
Unveiling Mechanisms of MRTX1133 Resistance
Recent years have seen major advances in KRAS G12D-targeted therapeutics. However, acquired drug resistance remains a significant clinical challenge, with...
Continue Reading
Recent years have seen major advances in KRAS G12D-targeted therapeutics. However, acquired drug resistance remains a significant clinical challenge, with...
Continue Reading
Acute myeloid leukemia (AML) remains a highly aggressive hematologic malignancy, responsible for over 100,000 deaths globally each year. The approval...
Continue Reading
Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, immune-mediated disorder characterized by persistent inflammation...
Continue Reading
KRAS mutations act as primary initiators of carcinogenesis in several major cancers and are present in approximately 20 – 25%...
Continue Reading
Introduction: RNA-based therapies are a frontier in biomedicine, with the potential to fundamentally change treatments for a wide range of...
Continue Reading
Evidence suggests that type 2 diabetes mellitus (T2DM) is associated with cognitive dysfunction and an increased risk of developing neurocognitive...
Continue Reading
Mechanisms, Recent Progress, and Animal Models Radionuclide drug conjugates (RDCs), a novel class of precision tumor-targeting therapeutic and diagnostic agents,...
Continue Reading
Current preclinical murine models of heart failure with preserved ejection fraction (HFpEF) require prolonged modeling periods, posing significant challenges for...
Continue Reading
Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, immune-mediated disorder characterized by persistent inflammation...
Continue Reading